<DOC>
	<DOCNO>NCT02716194</DOCNO>
	<brief_summary>1 . To assess tolerability safety BAX 826 single infusion previously treat patient ( PTPs ) severe hemophilia A 2 . To determine pharmacokinetic ( PK ) parameter BAX 826 compare ADVATE 3 . To evaluate immunogenicity polysialic acid link Factor VIII ( FVIII )</brief_summary>
	<brief_title>BAX 826 Dose-Escalation Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Previously treat male participant age 18 65 year ( inclusive ) time screen 2 . Diagnosis severe hemophilia A ( Factor VIII level &lt; 1 % ) 3 . Previously treat FVIII concentrate ≥150 document Exposure Days ( EDs ) 4 . Karnofsky performance score ≥60 5 . Human immunodeficiency virus negative ( HIV ) ; HIV+ stable disease 6 . Hepatitis C virus negative ( HCV ) ; HCV+ chronic stable hepatitis assess investigator 7 . Able understand provide write informed consent include signature inform consent form ( ICF ) approve ethic committee ( EC ) 8 . Have provide write authorization use disclosure protect health information 9 . Agree abide study schedule return require assessment 10 . Willing able comply requirement protocol 1 . Detectable FVIII inhibitor screening , titer ≥0.6 Bethesda Unit ( BU ) 2 . Documented history FVIII inhibitor titer ≥0.4 BU time prior screen 3 . Known clinical hypersensitivity towards mouse hamster protein polysialic acid ( PSA ) 4 . Scheduled elective surgery study participation 5 . Severe chronic hepatic dysfunction 6 . Severe renal impairment 7 . Currently receive , recently receive ( less 3 month prior study participation ) , schedule receive course study , PSAylated drug 8 . Have receive another investigational drug within 30 day prior study entry and/or schedule receive additional investigational drug course study context another investigational drug study 9 . Diagnosis inherit acquire hemostatic defect hemophilia A 10 . Currently receive , schedule receive course study , immunemodulating drug antiretroviral chemotherapy 11 . Has clinically significant medical , psychiatric cognitive illness recreational drug/alcohol use , opinion investigator , would affect safety compliance participant study 12 . Is family member employee investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>